Under the High Patronage of

Mr Emmanuel Macron

President of the French Republic

THANK YOU FOR

HYBRID 2024

Paris
February 8 and 9, 2024

#Hybrid2024 marks the second edition of this format. We also celebrate the 15th anniversary of the International Research Meetings (RIR Rencontres internationales de la recherche), launched in 2009 at the Élysée Palace to give French health research international visibility.

HYBRID is the convergence of a scientific congress, where the latest advances are presented by their authors, and B2B meeting sessions. For this edition, 50 academic teams selected by Inserm, 20 startups selected by Bpifrance, France Biotech, and Inserm Transfert, as well as international R&D teams from health industry, mobilized to make #Hybrid2024 a success.

On the agenda for #Hybrid2024: Over 350 participants selected by the steering committee from over 500 applications; 805 meeting requests and 337 B2B meetings honored; 24 presentations and 3 roundtable discussions.

We are proud and honored by the success of #Hybrid2024 and invite you to join us for the next edition, with one ambition and one motto: science and meetings.

HYBRID 

ARIIS - the health industry alliance for research and innovation, Bpifrance - the French Public Investment Bank, France Biotech - French trade association of biotechnology companies, INSERM - French National Institute of Health and Medical Research, and Leem - the French union of pharmaceutical industries have joined forces to organize HYBRID :

  • An international research and innovation meeting, bringing together academic researchers, start-ups and industry in Paris.

  • A unique opportunity to discover and meet the best of French research and innovation (research teams, start-ups) and international industrial teams.

  • A two-day event alternating keynotes, pitches and B to B meetings, paving the way for future collaborations and partnerships with the French innovation ecosystem.
Image

2024 Edition : NEXT GENERATION OF GENE AND CELL THERAPIES

  • Vector-derived gene therapy (viral and non viral)
  • Novel Genome editing approaches
  • Nucleic acid therapeutics
  • Cell therapies (universal cells, reprogrammed cells,…)
  • Next generation of CAR
  • Novel approaches such as Exosomes for delivery
  • Short-, medium- and long-term tolerance and toxicity

A COMPLETE ECOSYSTEM

HYBRID has been designed with the aim to go one step further compared to previous editions by:

  • Federating the French National Institute of Health and Medical Research INSERM together with the French industrial alliances (ARIIS), the French union of pharmaceutical companies (Leem), the French biotech alliance (France Biotech) and the French investment bank (Bpifrance)
  • Gathering top talented French scientists, promising French start-ups and international industry leaders during two days
  • Enhancing the entire French ecosystem and promoting public & private partnerships, a key generator for innovation
HYBRID_home_schema.jpg